Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
1:250 RS with possible uplist per 8/21/23 news
https://www.otcmarkets.com/stock/SKYE/news?id=411321
It means that the company/person (Corporate Compliance) who tried to get custodianship of the company was unable to.
Most likely they will withdraw their custodianship application. Custodians can only take over abandoned tickers (ones that don't file quarterly reports and that are not in good standing with the SOS). While this company has a revoked status in NV SOS, it is is already up to date in quarterly filings.
interesting. a custodian application was filed last week
https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=BOUZgtCNm-15Ka56fwVM3w2&tabIndex=3
FYI, RS filed last night
https://www.otcmarkets.com/stock/ybcn/disclosure
E-trade removed it from your account but it wasn't removed as worthless? TDA did this in my account:
05/02/2023 11:21:17 REMOVAL OF WORTHLESS SECURITIES (9BF994005)
just noticed this got removed as worthless from my TDA account on 5/2/23
custo granted
revival on NV SOS
you forgot? that's you, no? lol
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164342049
yup. it was the same AS on NV SOS
dissolved in NV to reincorporate in WY
yup. hopefully it runs up instead. not sure why so many sells today
new custos: SVLT, ITRX, SRCX
SVLT: https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=qxL4IyJ521LbUYJUcPS6hA2&tabIndex=3
ITRX: https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=ewa6a9fK-PEXwZVFJ0HJgg2&tabIndex=3
SRCX: https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=9Oh3vT5b2nUJYi9GTOGVzg2&tabIndex=3
news https://www.otcmarkets.com/stock/isco/news/story?e&id=1933958
International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease
CARLSBAD, CA / ACCESSWIRE / June 30, 2021 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today successful completion of its dose escalating phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT02452723) evaluating the safety, tolerability and preliminary efficacy of its lead candidate, ISC-hpNSC® for the treatment of Parkinson's disease (PD).
Dr. Andrew Evans, M.D., Director of Movement Disorders at the Royal Melbourne Hospital, the study's principal investigator commented: "The safety evaluation is based on the initial 12 months of safety data from the first cohort (low dose), the second cohort (mid dose), and the third cohort (high dose). In all three cohorts there have been no serious adverse effects related to the transplanted ISC-hpNSC® cells. Based on all data collected in the clinical trial the therapy is considered safe."
In order to gain initial insight into what dose might show the greatest efficacy we have continued observations on a biannual basis of these patients. All the patients in the clinical trial have now completed at least 24 months of total post-operative observations. Patients treated with the mid dose (cohort 2) have been observed for at least 36 months and patients in the low dose group (Cohort 1) have been followed for 48 months post transplantation.
"We are excited about our phase 1 clinical trial results. Patients, followed for over two years after cell transplantation, have reported, on average, improvements in a Parkinson's Disease specific measures, when compared to baseline evaluations. In this context, the results are very encouraging that the ISC-hpNSC® transplanted cells are not only well tolerated, but also may be effective" commented Dr. Russell Kern, ISCO's Executive Vice President and Chief Scientific Officer.
In terms of preliminary efficacy, where scores are compared against baseline before transplantation, we observed a potential dose-dependent response, with an apparent peak effectiveness at our middle dose. The % OFF-Time, which is the time during the day when levodopa medication is not performing optimally and PD symptoms return, decreased an average 47% from the baseline at 12 months post transplantation in cohort 2. This trend continued through 24 months where the %OFF time in the second cohort dropped by 55% from the initial reading. The same was true for % ON-Time without dyskinesia, which is the time during the day when levodopa medication is performing optimally without dyskinesia. The % ON-Time increased an average of 42% above the initial evaluation at 12 months post-transplantation in the second cohort. The %ON result improved in the second cohort to 65% above the baseline in month 24. The quality of life of the patients as measured by the Parkinson's Disease Quality of Life Score-39 (PDQ-39) Summary Index, improved 43% for the second cohort at twelve months post-transplantation. This improved to a 45% better score in cohort 2 at 48 months.
About the clinical study
The Phase 1 clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into patients with Parkinson's disease. The open-label, single center, uncontrolled clinical trial is evaluating three different dose regimens of 30 million to 70 million neural cells. A total of 12 participants with Parkinson's disease were treated. Following transplantation, the patients were monitored for 12 months at specified intervals to evaluate the safety and biologic activity of ISC-hpNSC®. A PET scan was performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr as well as other rating scales. An extension phase of the study will evaluate patients every 6 months for 5 additional years.
About Parkinson's disease
Parkinson's disease is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement related. These symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease. Depression is the most common psychiatric symptom. Parkinson's disease is more common in people over the age of 50. There are no approved treatments that restore the damaged dopaminergic neurons. Medications typically used in the treatment of Parkinson's disease, levodopa and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective, while at the same time frequently producing a complication marked by involuntary writhing movements. There are over 10 million people afflicted with Parkinson's disease, worldwide. In 2013 Parkinson's disease resulted in about 103,000 deaths, globally. In 1990, the death toll recorded was 44,000.
About ISC-hpNSC®
International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are free of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and neuroregeneration to the dying dopaminergic neurons of the recipient Parkinson's disease brain. Additionally, ISC-hpNSC® is safe, well tolerated and has shown not to cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide, through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
Safe harbor statement
Statements pertaining to anticipated developments, clinical studies expectations, potential additional applications for ISC-hpNSC®, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: ir@intlstemcell.com
SOURCE: International Stem Cell Corporation
View source version on accesswire.com:
https://www.accesswire.com/653700/International-Stem-Cell-Corporation-Announces-Successful-Completion-of-Its-Phase-1-Clinical-Trial-in-Parkinsons-Disease
© Copyright 2021 ACCESSWIRE. All Rights Reserved.
Since the existing Pres reinstated it a few days ago, it was being contested, so the custodians decided to drop the custodianship
custo denied
The Court DENIES Petitioner's Application for the Appointment of Custodian, without prejudice, for failure to fully comply with NRS 78.347(2)(e). Petitioner's Affidavit fails to adequately detail "reasonable efforts by the applicant to contact the officers and directors of the corporation." NRS 78.347(2)(e). This department requires a showing similar to that for requests to Enlarge Time for Service/Service by Publication (i.e. "skip tracing"; checking the phone book, utility records, postal service, DMV, voter registration rolls, property ownership records, and other means of garnering information of public record). Petitioner may revise and resubmit. The provided proposed Order shall be discarded. CLERK'S NOTE: This Minute Order was electronically served to all registered parties for Odyssey File & Serve. clm 06/24/21
custo granted
IWAL DeNunzio custo
DeNunzio custo
custo filed yesterday by Alpharidge
hopefully!
custodianship Moody/DeNunzio
revival on NV SOS
custodianship application by G Reed Petersen
custodianship application by G Reed Petersen
officers changed on NV SOS
news!
http://www.globenewswire.com/news-release/2021/02/11/2174338/0/en/AngioSoma-and-its-Subsidiary-SomaCeuticals-Announce-Amended-and-Restated-Execution-of-Global-License-for-Multiple-Sclerosis-Patent.html
AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent
Email Print Friendly Share
February 11, 2021 10:42 ET | Source: AngioSoma, Inc.
Houston, TX, Feb. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 has been amended and restated as of February 4, 2021 to give both parties a stronger and more robust platform to move synergistically forward to market and license Patent 10,619,592 issued to Fabrizio de Silvestri as inventor.
Fabrizio de Silvestri stated, “It is wonderful that Jim Katzaroff and his group are actively interviewing Contract Research Organizations as well as possible funding sources. This looks to be a very exciting and critical year for AngioSoma.”
"I am so delighted that Jim was able to complete this transaction in a favorable manner to both parties. Now Jim will work with alacrity towards trials, and if we receive favorable results, navigate towards commercialization," stated Alexanderia Blankenship, CEO and President of the Company.
About AngioSoma, Inc.
AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products and medical devices to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals™.
Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com. Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook.
Notice Regarding Forward Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
CONTACT
AngioSoma, Inc.
James C. Katzaroff
President, SomaCeuticals, Inc.
(832) 781-8521
http://www.globenewswire.com/news-release/2021/02/02/2168567/0/en/OTC-ILUS-Partners-With-Milanion-Group-to-Integrate-ILUS-Technologies-With-Milanion-Autonomous-Vehicle-Technology.html
OTC:ILUS Partners With Milanion Group to Integrate ILUS Technologies With Milanion Autonomous Vehicle Technology
Email Print Friendly Share
February 02, 2021 14:57 ET | Source: ILUS International Inc.
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ILUS International Inc (OTC: ILUS): ILUS is a M&A company acquiring technology-based companies globally and has recently completed its acquisition of FB Technologies Global Inc (FireBug Group), a leading manufacturer of Technology & Fire & Rescue Vehicles including its EV (Electric 6 x 6 vehicle) to the Fire & Rescue market. The Fire & Rescue market globally has been under invested for decades and is now experiencing significant modernisation, due to the rapid urbanisation of the cities becoming wider, taller and more congested making it increasingly costly and difficult for Fire & Rescue services to perform efficiently. FireBug technology is based on water efficiency and water saving. The technology is at least 63% more efficient than conventional technologies allowing responders to utilise much smaller faster and more economical response vehicles in most instances. A common scenario is where conventional technology would use approximately +/-200 gallons of water to extinguish a car fire in about 90 seconds. In comparison the FireBug technology would use 10 gallons in +/- 7 seconds. In order to facilitate its global rollout, ILUS has an acquisition strategy to roll up strategic companies to increase its route to market and manufacturing capacity and to continually develop the technology platform further. On this basis FB Technologies Global is very pleased to sign a Memorandum of Understanding with Milanion Group LLC, a UK and Dubai based specialist technology company disrupting the market in the design, development, and manufacture of unmanned systems that serve to augment and transform team and mission capabilities whilst safeguarding personnel in hostile and dangerous environments in both the public and private sector, globally. Leading with the versatile and fully amphibious AGEMA UGV with its modular design to cater for a range of payloads, Milanion Group also provide USV solutions in the form of unmanned fully autonomous rapid response vessels for Marine applications. Jointly the companies intend to develop an autonomous unmanned Fire & Rescue solution for the Military, Fire & Rescue and specialist applications. Jointly the companies have been working on solutions for many months for several major Military and Civil Defense departments. Further to the Fire, Rescue & Emergency provision, the companies jointly will look to develop the Milanion autonomous technology onto the ILUS E-raptor EV 6x6 UTV.
Beyond this partnership, it is expected that ILUS will announce further details of their 2 possible imminent acquisitions later this week.
For further information on the companies please see their communication channels website: www.ilus-group.com
Twitter : OTC_ILUS
Contact:
Nicolas Link CEO
email : nick.link@ilus-group.com
Irina Shatalova PhD,MBA,
(PA to the CEO and Investor Relations)
Email: Irina.Shatalova@ilus-group.com
Website: https://milaniongroup.com
Email : ssingh@milaniongroup.com
Related Links
http://ilus-group.com
https://milaniongroup.com
http://raptor-utv.com
Media Contact
ILUS International Inc
Nick.link@ilus-group.com
917 522 3202
New York
http://www.ilus-group.com
Source : ILUS International Inc (OTC:ILUS)
boom. 0145... next stop 02 imo
https://stockcharts.com/h-sc/ui?s=soan&p=D&yr=0&mn=26&dy=0&id=p00231052056